NCT04959799 - Dalbavancin Real-life Utilization in Diabetic Patients Suffering From Infections (DALBADIA) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 2, 2022

Primary Completion Date

May 31, 2022

Study Completion Date

May 31, 2022

Conditions

DiabetesInfection

Interventions

DRUG

Dalbavancin

Adult diabetic patients suffering from infections who received the last dose of dalbavancin according to the current standard clinical practice at least 30 (+7) days before enrolment in the study.

Trial Locations (11)

14100

Ospedale Cardinal Massaia, Asti

18014

Hospital Universitario Virgen de las Nieves, Granada

28046

Hospital Universitario La Paz, Madrid

28922

Hospital Universitario Fundación Alcorcón, Alcorcón

33100

Azienda Sanitaria Universitaria Friuli Centrale, Udine

46026

Hospital Universitario y Politécnico La Fe, Valencia

56124

A.O.U. Pisana Presidio Ospedaliero Cisanello, Pisa

80131

Azienda Ospedaliera Universitaria Federico II, Napoli

90127

"Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone", Palermo

Unknown

ASST dei Sette Laghi, Varese

08036

Hospital Clinic, Barcelona

All Listed Sponsors

collaborator

Iqvia Pty Ltd

INDUSTRY

lead

Aziende Chimiche Riunite Angelini Francesco S.p.A

INDUSTRY